๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mendus AB (publ) (STO:IMMU)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
3.500
+0.070 (2.04%)
Nov 20, 2026, 5:29 PM CET

Mendus AB Earnings Call Transcripts

Fiscal Year 2026

  • VITAL-CML cleared its safety stage, while early immune signals in AML and CML support continued development of vididencel. Cash was SEK 55.7 million at quarter-end, with runway into Q2 2027; key trial readouts are expected through 2027.

  • Clinical development advanced with the ADVANCE II trial reaching five-year survival and the CADENCE trial confirming safety and enrollment milestones. Financial discipline reduced costs and extended cash runway into Q1 2027. Multiple clinical readouts and U.S. expansion are planned, contingent on further financing.

  • Clinical programs in AML and CML advanced, with reduced costs and a strengthened cash position. Recruitment in key trials is ongoing, with interim results expected mid-year and a focus on broadening patient eligibility.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021